Project Grant R01CA298333
Award Date 9/16/25
Completion Date 8/31/29
Dollars Obligated $3M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
- This Project Grant award of $662,938, provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), supports research at Northwestern University to investigate the role of gain-of-function mutant p53 proteins in acute myeloid leukemia (AML). The central objective is to determine how these p53 mutations promote leukemia-initiating cell self-renewal, chromatin accessibility, and 3D chromatin structure, which may contribute to therapy resistance in AML....
- The National Cancer Institute awarded a $1,542,555 Project Grant to Sloan-Kettering Institute For Cancer Research under the Cancer Treatment Research program (CFDA 93.395). The grant will fund research from December 2022 through November 2027 to develop more effective treatments for localized bladder cancer. Specifically, the grantee will conduct genomic analyses of bladder cancer patient cohorts to validate DNA damage response mutations as predictors of sensitivity to bacillus Calmette-Guérin...
- This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $661,072 to Northwestern University to develop a novel, first-in-class small molecule inhibitor that targets the USP22 oncogene. The goal is to create a therapy with dual immuno-activating and cancer-targeting efficacy to treat triple negative breast cancer. The research, conducted in partnership with startup company Exomira Medicine Inc., aims to advance the therapeutic...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $583,973.00 to the Sloan-Kettering Institute for Cancer Research to investigate the role of EP300 mutations in bladder cancer pathogenesis and drug response. The key objectives are to: Study how EP300 loss-of-function mutations mediate resistance to FGFR inhibitors like erdafitinib using patient-derived bladder cancer models. Identify genomic alterations, especially EP300...
- This $521,579 Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), supports research to identify critical regulators controlling clear cell renal cell carcinoma (CCRCC) lung metastasis. The University of Texas Southwestern Medical Center, the awardee, will conduct a genome-wide CRISPR screen to characterize the role of the hepatic leukemia factor (HLF) in CCRCC lung metastasis and examine the underlying molecular...
- This $640,135 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a new generation of potent menin inhibitors that can overcome resistance observed in current menin inhibitor treatments for acute myeloid leukemia (AML) patients. The award recipient, the Regents of the University of Michigan, will leverage its expertise in medicinal chemistry and cancer biology to design and test these next-generation menin...
- This Project Grant award of $545,983.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at Northwestern University to study the role of the protein PlexinB2 in the metastasis of triple-negative breast cancer (TNBC). The goal is to identify molecular regulators of the interactions between circulating tumor cells (CTCs) and the host immune system, with the objective of developing strategies to inhibit TNBC metastasis. The project will run from...
- The National Cancer Institute (NCI), part of the Department of Health and Human Services, awarded a $1,274,742 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Northwestern University. The project aims to engineer a high-performing microfluidic system for the rapid, non-invasive isolation and expansion of circulating tumor-reactive lymphocytes (CTRLs) from blood samples. This innovation could accelerate the development of effective anti-tumor cellular...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $342,102.00 to The Johns Hopkins University to elucidate the role of the chromatin regulator HMGA1 in KMT2A-rearranged acute myeloid leukemia (AML). KMT2A-rearranged AML is an aggressive form of leukemia that is resistant to current therapies. The project aims to investigate how HMGA1 drives leukemogenesis and therapy resistance in this disease, with the goal of informing the...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $570,096 to Northwestern University to conduct research on the role of the EZH2 protein in prostate cancer progression. The project aims to investigate how dysregulation of EZH2 affects RNA modifications, such as N6-methyladenosine (m6A), and how these epigenetic changes contribute to the development of advanced, treatment-resistant prostate cancer. The research seeks to uncover new...